Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × Maintenance × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 3 Smoldering Multiple Myeloma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Leukemia, Promyelocytic, Acute 1 Leukemia, Myeloid, Acute 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 19 Dexamethasone 16 Bevacizumab 16 Oxaliplatin 14 Docetaxel 14 Cyclophosphamide 12 Capecitabine 12 Gemcitabine 11 Sorafenib 10 Leucovorin 10 Fluorouracil 10 Carboplatin 10 Epoetin Alfa 9 pembrolizumab 8 Pemetrexed 8 Fentanyl 8 venetoclax 7 atezolizumab 7 Rivaroxaban 7 Prednisone 7 Drug Therapy 7 Doxorubicin 7 Anastrozole 7 Rituximab 6 Ondansetron 6 Morphine 6 Irinotecan 6 Denosumab 6 Cisplatin 6 Tranexamic Acid 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07207824 2025-10-06

HERO

Fudan University

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡